- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.09. | Child dies in Capsida study of rare disease gene therapy | ||
| 11.09. | FDA shares guidance to drugmakers developing non-opioid pain medicines | ||
| 10.09. | FDA clears J&J's drug-device combo for bladder cancer | ||
| 10.09. | Kriya, Odyssey secure 'megarounds'; Amgen boosts R&D leadership | ||
| 10.09. | Novo Nordisk to lay off 9,000 workers in major restructuring | ||
| 10.09. | [Podcast] The Progress Profile: Alzheimer's Research in Focus | ||
| 09.09. | Lilly to give biotech startups access to AI tools | ||
| 09.09. | Novartis to gain heart drug in $1.4B deal for Tourmaline Bio | ||
| 09.09. | BioNTech says dual-acting lung cancer drug helped shrink tumors | ||
| 08.09. | A new class of sleep drugs draws Wall Street's attention | ||
| 08.09. | Pfizer, BioNTech showcase new data supporting COVID booster | ||
| 08.09. | New Summit data clouds approval pathway in lung cancer | ||
| 08.09. | Rapport shares double on better-than-expected seizure drug data | ||
| 08.09. | A UK biotech takes aim at Parkinson's, ALS by drugging mitochondria | ||
| 08.09. | Driving precision oncology development: Integrated biomarker testing solutions that deliver impact | ||
| 08.09. | How sponsors are staying ahead in the obesity trial landscape | ||
| 08.09. | Harnessing the power of AI to detect ATTR-CM | ||
| 05.09. | FDA to publish CRLs in real time; PEPFAR to distribute Gilead's Yeztugo | ||
| 05.09. | Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug | ||
| 04.09. | At Senate hearing, lawmakers express dissatisfaction with RFK Jr.'s vaccine moves | ||
| 04.09. | Atlas Venture reels in $400M to grow its biotech startups | ||
| 04.09. | FDA outlines new review pathway for drugs treating ultra-rare diseases | ||
| 04.09. | Sanofi's touted eczema drug hits study goal, but data fall short of expectations | ||
| 04.09. | A drug discovery startup banks $150M for immune and obesity drugs | ||
| 03.09. | Biohaven's rare disease drug is 'ready to ship on Day 1' following FDA approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .